Rennova Health, Inc. announced its board of directors boasting years of experience in executive leadership, healthcare, public policy, and financial services. Following the merger between Medytox Solutions, Inc. and CollabRx, Inc. on November 2, 2015, Rennova Health, Inc.'s board includes the following seven members: Thomas R. Mika, MBA, as executive chairman of the board; Paul R. Billings, MD, PhD, FACP, FACMG, as director; Michael L. Goldberg as director; Robert Lee as director; Christopher E. Diamantis as director; Benjamin Frank as director; and Seamus Lagan as director. Thomas R. Mika, MBA, now holds the position of executive chairman of the board.

Prior to his leadership role at CollabRx, Mika was appointed president and CEO of Tegal in 2005 and chairman of the board the following year. Paul R. Billings, M.D., Ph.D., FACP, FACMG, is director of the board. Dr. Billings has devoted his career to improving patient care by expanding the use of medically relevant genomic technologies in clinical settings, most recently as Chief Medical Officer of Life Technologies, Inc. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept.

of Veterans Affairs, and the National Academy of Sciences Institute of Medicine's Roundtable on Genomics. Christopher E. Diamantis has served since 1999 as chairman and CEO of Integrated Financial Settlements, Inc. He also has been, since April 2000, director and managing partner of the Gabor Agency, Inc. Benjamin Frank is a retired lawyer and businessman, with particular experience in healthcare, foreign trade, retail, business development, and government. He served from 1971 to 1987 as vice president and trustee of North Shore University Hospital, currently North Shore University Hospital, Long Island Jewish Hospital System.

Michael L. Goldberg is the managing director of Monarch Capital, LLC. He has also served as a consultant to a number of private and public companies to assist in formation and capital structure. Seamus Lagan brings over 20 years' experience in the restructure, development, and management of startup and small companies in both the private and public sector.

Mr. Lagan was the CEO of the two main subsidiaries of Medytox since 2011, whereupon he was appointed CEO of Medytox Solutions, Inc. in October 2014, and has been a key factor in both the merger of the two companies and the development of Rennova's business plan. Robert Lee is the managing partner of Sheffield Investment Partners, a position he has held since 2010. From 2008 to 2010, Mr. Lee served as managing director of New Stream Capital, and from 2000 to 2007, he was managing director at CRT Capital Group.